Xeris Pharmaceuticals (NSDQ:XERS) announced today that it achieved a milestone for the payor coverage of its Gvoke glucagon injection.
Approximately 91% of Medicare patients, 88% of commercially insured patients and a growing number of Medicaid lives have unrestricted access to Gvoke, Xeris said in a news release.
Chicago-based Xeris’ Gvoke, a ready-to-use pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia for people with diabetes ages 2 and above. The company recently entered into a $71 million licensing agreement for Gvoke (Ogluo in Europe) with Tetris Pharma.
Xeris said over 240 million total lives have unrestricted access to Gvoke, with 3 million Illinois Medicaid lives set to be added effective Oct. 1, 2021.
“Delivering cost-effective access to high-quality care is a top priority for Xeris,” Xeris chairman & CEO Paul R. Edick said in the release. “By achieving such outstanding payor coverage, in combination with our $0 copay program, many more of the at-risk patient population can and should have Gvoke. This is especially important now, as children are going back to school and many people are picking up or refilling their glucagon, to make sure they get a ready-to-use glucagon, such as Gvoke.”
The $0 copay program is only valid for commercially eligible patients. It does not apply to beneficiaries of Medicaid, TRICARE or other federal or state health programs.
